Telix Pharmaceuticals (NASDAQ:TLX) Issues Earnings Results

Telix Pharmaceuticals (NASDAQ:TLX) issued its earnings results on Thursday. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.01, FiscalAI reports. The company had revenue of $238.50 million for the quarter, compared to analyst estimates of $479.63 million.

Telix Pharmaceuticals Price Performance

Telix Pharmaceuticals stock opened at $12.12 on Thursday. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $12.60. The company’s fifty day moving average price is $10.87 and its two-hundred day moving average price is $9.60. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Institutional Trading of Telix Pharmaceuticals

Several large investors have recently made changes to their positions in TLX. Vident Advisory LLC acquired a new position in shares of Telix Pharmaceuticals during the 4th quarter valued at about $204,000. XTX Topco Ltd acquired a new position in Telix Pharmaceuticals during the fourth quarter valued at approximately $89,000. Quadrature Capital Ltd bought a new position in shares of Telix Pharmaceuticals in the fourth quarter valued at approximately $276,000. OLD Mission Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter worth $111,000. Finally, Lazard Asset Management LLC lifted its stake in shares of Telix Pharmaceuticals by 118.6% in the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock worth $1,876,000 after buying an additional 135,893 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Monday, July 6th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday. Finally, Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.